This contract is with an existing client, and has a minimum value of $579,000. The contract brings the total value of US pharmaceutical trial contracts secured over the past 11 months to $7.9 million, said AtCor.
Duncan Ross, CEO of AtCor Medical, said: “We are again very pleased to announce additional business from an existing client. AtCor’s strong customer retention in new clinical trials demonstrates the importance of noninvasive central blood pressure data in drug development, as well as the high quality of the services we provide.”